AVITA Medical Reports First Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Cantor Fitzgerald Says Buy Avita Medical Ltd. (RCEL) on Weakness Following Q1 Results
May 9, 2025 10:13 AM EDTCantor Fitzgerald analyst Ross Osborne reiterated an Overweight rating and $19.00 price target on Avita Medical Ltd. (NASDAQ: RCEL) following Q1 results, saying they would buy on today's weakness. The stock is down 22% in early trading.
The analyst commented, "We reiterate our Overweight rating and... More
